Oncology Pharma Inc (ONPH) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Oncology Pharma Inc $0.06, price $0.06, upside +0.0%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc.
Show more
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.
Stock analysis
Oncology Pharma Inc (ONPH) currently trades at $0.0600, while our model-based Fair Value estimate is $0.0600, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.1300 per share, and 2 of the 5 models we run sit above the $0.0600 price.
Bear case: the Asset-Based group reads lowest at $0.0200, and 3 of the 5 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Financial Services sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Oncology Pharma Inc reported revenue of $10.2K in FY2013 versus $3.7M in FY2002, a compound −41.4%/yr. Reported net income was −$5.8K in FY2026.
Key figures
Market cap $2.3M · Net margin 1,821% · Return on assets (EBIT) −1,189% · Operating margin −75.0% · Revenue (TTM) $10.2K · Free cash flow $369K · Net debt $658K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).
What moves the price
The share trades about 56% below its 52-week high and 59,900% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −18% fair-value upside, at 0%, ONPH screens cheaper than that median.
Fair Value models
Bear $0.0600Fair Value $0.0600Bull $0.0600
Price $0.0600 · Upside +0.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−266.3% (1996) → −141.7% (2013)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −0.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Shell Companies · 65 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside+0.0% · Above median
Profitability
Return on assets0.0% · Top 25%
Operating margin (TTM)−75.0% · Bottom 25%
Growth and dividend
Revenue growth0.0% · Top 25%
Valuation Multiplesvs Shell Companies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Oncology Pharma Inc (ONPH) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.0600 versus a price of $0.0600, about +0% upside (fairly valued).
What is the fair value of ONPH?
Our model-based fair value for Oncology Pharma Inc is $0.0600 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.0600.
What is the quality score of ONPH?
Oncology Pharma Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oncology Pharma Inc (ONPH)?
Our model-based price target is the fair value of $0.0600 (as of Oct 3, 2026) from 5 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Oncology Pharma Inc stock forecast for 2026?
Our models put fair value at $0.0600, about +0% upside versus a price of $0.0600 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Oncology Pharma Inc (ONPH)?
Oncology Pharma Inc reported trailing-twelve-month revenue of about $10.2K (latest available figure, as of Oct 3, 2026).
What growth is priced into Oncology Pharma Inc (ONPH)?
For today's price to be fair in a discounted-cash-flow model, Oncology Pharma Inc would have to grow free cash flow by +2.2 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 9 years revenue grew -41.0 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of ONPH use?
Our models discount Oncology Pharma Inc at 9.7 %: a base by market capitalisation (nano), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Oncology Pharma Inc that is +2.2 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Oncology Pharma Inc (ONPH) delivered so far?
Over the past 9 years revenue at Oncology Pharma Inc grew -41.0 % a year. The price currently implies +2.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Oncology Pharma Inc (ONPH) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Oncology Pharma Inc (+2.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Oncology Pharma Inc (ONPH)?
The free-cash-flow yield on the price is 7.48 %: that much free cash flow Oncology Pharma Inc produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Oncology Pharma Inc (ONPH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oncology Pharma Inc it is $0.0600 per share (as of Oct 3, 2026), against a price of $0.0600. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is Oncology Pharma Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, ONPH trades below its calculated fair value: price $0.0600, fair value $0.0600, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONPH?
No. The price is what the market pays today ($0.0600); the fair value is what the company's own numbers justify ($0.0600). For Oncology Pharma Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oncology Pharma Inc worth?
The market values Oncology Pharma Inc at about $2.3M (market capitalisation, as of Oct 3, 2026). Per share that is $0.0600; our models calculate a fair value of $0.0600 per share.
How far is ONPH from its 52-week high?
Oncology Pharma Inc trades at $0.0600, about 56% below its 52-week high of $0.1350 and 59,900% above the low of $0.0001 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0600 is for.
Which stocks are comparable to Oncology Pharma Inc?
From the same area (Financial Services) we also value Lionheart III Corp, AA Mission Acquisition Corp, Berto Acquisition Corp, Metals Acquisition Corp, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oncology Pharma Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $0.0600, calculated fair value $0.0600 (+0%), Quality Score 40/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONPH calculated?
We run Oncology Pharma Inc through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Oncology Pharma Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oncology Pharma Inc (ONPH)?
The closing price on Oct 2, 2026 was $0.0600. Our model-based fair value is $0.0600, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oncology Pharma Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Key figures of Oncology Pharma Inc
How large is the market capitalisation of Oncology Pharma Inc (ONPH)?
The market capitalisation of Oncology Pharma Inc is $2.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of Oncology Pharma Inc (ONPH)?
The net margin of Oncology Pharma Inc is 1,821% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Oncology Pharma Inc (ONPH)?
On an EBIT basis the return on assets of Oncology Pharma Inc is −1,189% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oncology Pharma Inc (ONPH)?
The operating margin of Oncology Pharma Inc is −75.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much net debt does Oncology Pharma Inc (ONPH) carry?
The net debt of Oncology Pharma Inc is $658K (fiscal year 2022, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Oncology Pharma Inc in the live analysis
One click puts Oncology Pharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 3, 2026